Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil

Conditions

• Breast Cancer

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Trastuzumab deruxtecan — DRUG
  Patients with RE\<10% and HER2-Low breast cancer that have received Trastuzumab-deruxtecan in the metastatic setting

Study Details

A national, multicenter, retrospective, observational study (Real-World Evidence-RWE) aimed to assess the efficacy of Trastuzumab-deruxtecan (T-DXd) in patients with triple-negative (RE\<10%) metastatic HER2-Low breast cancer.

Key Dates

First listed

Jan 30, 2024

Start date

Dec 4, 2023

Status verified

Apr 2025

Primary completion

Mar 26, 2024

Completion

Mar 26, 2024

Study Design

Enrollment

2 participants (actual)

Arms

• Arm: Trastuzumab-deruxtecan

Primary Outcome Measure

Time to Next Treatment [ Time Frame: Through study completion, an average of 1 year ]

Find similar trials

Related Studies

• Collection of Blood From Patients With Cancer
  Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland
• Harvesting Cells for Experimental Cancer Treatments
  Enrolling By Invitation · National Cancer Institute (NCI) · Bethesda, Maryland
• High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast Cancer
  Recruiting · Carol Fabian, MD · Kansas City, Kansas
• Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies
  Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland